Azithromycin (ophthalmic) indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 13: | Line 13: | ||
* [[Streptococcus pneumoniae]] | * [[Streptococcus pneumoniae]] | ||
Efficacy for this organism was studied in fewer than 10 infections. | Efficacy for this organism was studied in fewer than 10 infections.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = |title = AZASITE (AZITHROMYCIN) SOLUTION [INSPIRE PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dc0f75a-1e14-469f-af4f-c668a32f2328 |publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 21:41, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications And Usage
AzaSite® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms:
- CDC coryneform group G1
- Haemophilus influenzae
- Staphylococcus aureus
- Streptococcus mitis group
- Streptococcus pneumoniae
Efficacy for this organism was studied in fewer than 10 infections.[1]
References
Adapted from the FDA Package Insert.